dendritic cell vaccine therapy

Phase 2Vaccine

dendritic cell vaccine therapy is one of 34 biologic programs targeting Advanced Malignancies. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Advanced MalignanciesActive, not recruiting

Advanced MalignanciesPhase 2

Active, not recruiting

Competition

Competitive Landscape

43 competitors in Advanced Malignancies

#DrugCompanyPhaseTrials

Lenvima

Eisai

Phase 3

2 2

Elunate

Takeda

Phase 3

1 3

Zaniducla

Jazz Pharmaceuticals

Phase 3

1 4

Beyfortus

BeiGene

Phase 3

1 5

Alimta

SShawn Eagle

Phase 3

5 6

Keytruda

Merck & Co.

Phase 2

11 7

Temodar

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 3

1 8

Taxol

Teva

Phase 2

8 9

Gemzar

Johnson & Johnson

Phase 2

7 10

Opdivo

Bristol-Myers Squibb

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 2Active, not recruiting

Advanced Malignancies

NCT01697527

Clinical

Trials by Indication[1]

Melanoma3 trials

Vaccine Therapy in Treating Patients With Stage IV or Relapsed Malignant Melanoma

Completed·JJonsson Comprehensive Cancer Center·Phase 1·NCT00005617

Vaccine Therapy in Treating Patients With Stage IV Melanoma

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00003665·40 enrolled

Vaccine Therapy in Treating Patients With Stage IV or Recurrent Malignant Melanoma

Completed·JJonsson Comprehensive Cancer Center·Phase 1/2·NCT00039325·28 enrolled

Advanced Malignancies1 trial

Gene and Vaccine Therapy in Treating Patients With Advanced Malignancies

Active, not recruiting·JJonsson Comprehensive Cancer Center·Phase 2·NCT01697527·6 enrolled

Glioma1 trial

Peptide-Pulsed Dendritic Cell Vaccination in Combination With Nivolumab and Ipilimumab for the Treatment of Recurrent and/or Progressive Diffuse Hemispheric Glioma, H3 G34-mutant

Withdrawn·JJonsson Comprehensive Cancer Center·Phase 1·NCT05457959

Lymphoma1 trial

Vaccine Therapy With or Without Cryosurgery in Treating Patients With Residual, Relapsed, or Refractory B-Cell Non-Hodgkin Lymphoma

Completed·MMayo Clinic·Phase 1·NCT01239875·16 enrolled

Kidney Cancer1 trial

Vaccine Therapy in Treating Patients With Advanced Kidney Cancer

Completed·JJonsson Comprehensive Cancer Center·Phase 1·NCT00004880·14 enrolled

2 more indications

Locally Advanced1 trial

Gene-Modified T Cells, Vaccine Therapy, and Ipilimumab in Treating Patients With Locally Advanced or Metastatic Malignancies

Terminated·JJonsson Comprehensive Cancer Center·Phase 1·NCT02070406·4 enrolled

Recurrent Glioblastoma1 trial

Phase I Surgical Trial to Evaluate Early Immunologic Pharmacodynamic Parameters for the PD-1 Antibody Pembrolizumab With Autologous Tumor Lysate-Pulsed Dendritic Cell Vaccination in Patients With Surgically Accessible Recurrent/Progressive Glioblastoma

Completed·JJonsson Comprehensive Cancer Center·Phase 1·NCT04201873·46 enrolled

Sources

References

[1]
ClinicalTrials.gov — 9 trial records for dendritic cell vaccine therapy. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — dendritic cell vaccine therapy compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for dendritic cell vaccine therapy. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Jonsson Comprehensive Cancer Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Vaccine[2]
Highest Phase: Phase 2[1]
Company: JJonsson Comprehensive Cancer Center

dendritic cell vaccine therapy

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Melanoma3 trials

Advanced Malignancies1 trial

Glioma1 trial

Lymphoma1 trial

Kidney Cancer1 trial

Locally Advanced1 trial

Recurrent Glioblastoma1 trial

References

Drug Info

Quick Facts

Related News